non-small cell lung cancer

AZ gets China nod for Tagrisso in first-line lung cancer
Pharmaforum
Wed, 09/4/19 - 11:22 am
AstraZeneca
China
Tagrisso
non-small cell lung cancer
Amgen’s ‘White Whale’ Cancer Data May Send Shares to Record High
Bloomberg
Wed, 09/4/19 - 10:20 am
Amgen
AMG 510
colon cancer
non-small cell lung cancer
Roche scores double cancer approval for new Bayer rival Rozlytrek
Fierce Pharma
Thu, 08/15/19 - 11:32 pm
Roche
Rozlytrek
FDA
NTRK fusion-positive tumors
non-small cell lung cancer
MSD’s Keytruda plus chemo backed by NICE for lung cancer
Pharmaforum
Fri, 08/9/19 - 10:30 am
Merck
Keytruda
NICE
non-small cell lung cancer
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Tue, 06/4/19 - 12:16 pm
Novartis
ASCO 2019
Incyte
MET inhibitors
capmatinib
non-small cell lung cancer
ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR
Fierce Biotech
Mon, 06/3/19 - 11:43 am
ASCO 2019
clinical trials
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Pharmaceutical Business Review
Mon, 06/3/19 - 11:29 am
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
Turning Point sinks on ASCO update for repotrectinib
BioCentury
Fri, 05/31/19 - 11:59 pm
ASCO 2019
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Wed, 05/15/19 - 11:52 pm
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
FDA expands Keytruda approval for first-line NSCLC treatment
Pharmaforum
Fri, 04/12/19 - 11:26 am
Merck
Keytruda
FDA
non-small cell lung cancer
Liquid biopsy is as effective as tissue biopsy in lung cancer, study finds
BioPharma Dive
Sun, 03/3/19 - 07:01 pm
Guardant Health
liquid biopsy
non-small cell lung cancer
Guardant360
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Fri, 02/8/19 - 11:40 am
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo
Xconomy
Thu, 01/24/19 - 10:57 am
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC
Fierce Biotech
Fri, 11/16/18 - 12:19 pm
AstraZeneca
clinical trials
tremelimumab
non-small cell lung cancer
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer
Fierce Pharma
Fri, 11/16/18 - 12:10 pm
China MediTech
Elunate
Eli Lilly
China
non-small cell lung cancer
Investors ding Tesaro despite responses for combo in NSCLC
BioCentury
Sat, 11/10/18 - 12:44 pm
Tesaro
non-small cell lung cancer
clinical trials
TSR-042
FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC
BioCentury
Sat, 10/20/18 - 11:13 pm
Bristol-Myers Squibb
Opdivo
FDA
EMA
Yervoy
non-small cell lung cancer
Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC
Pharmaceutical Business Review
Fri, 10/19/18 - 10:53 pm
Daiichi Sankyo
non-small cell lung cancer
DS-1205
TP Therapeutics Secures $80 Million Mezzanine Financing
CP Wire
Fri, 10/19/18 - 11:44 am
TP Therapeutics
non-small cell lung cancer
repotrectinib
Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop
Endpoints
Fri, 10/19/18 - 09:40 am
Merrimack Pharmaceuticals
MM-121
non-small cell lung cancer

Pages